We are live on ! Find out more
GILD icon

Gilead Sciences

1,575 hedge funds and large institutions have $73.2B invested in Gilead Sciences in 2017 Q4 according to their latest regulatory filings, with 202 funds opening new positions, 535 increasing their positions, 691 reducing their positions, and 116 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more first-time investments, than exits

New positions opened: 202 | Existing positions closed: 116

5% more funds holding

Funds holding: 1,5041,575 (+71)

1.25% more ownership

Funds ownership: 76.99%78.25% (+1.3%)

10% less capital invested

Capital invested by funds: $81.5B → $73.2B (-$8.37B)

23% less repeat investments, than reductions

Existing positions increased: 535 | Existing positions reduced: 691

40% less call options, than puts

Call options by funds: $1.57B | Put options by funds: $2.63B

46% less funds holding in top 10

Funds holding in top 10: 9652 (-44)

Holders
1,575
Holders Change
+71
Holders Change %
+4.72%
% of All Funds
35.71%
Holding in Top 10
52
Holding in Top 10 Change
-44
Holding in Top 10 Change %
-45.83%
% of All Funds
1.18%
New
202
Increased
535
Reduced
691
Closed
116
Calls
$1.57B
Puts
$2.63B
Net Calls
-$1.06B
Net Calls Change
-$328M
Name Holding Trade Value Shares
Change
Change in
Stake
MFBTD
526
MB Financial Bank - Trust Department
Illinois
$4.84M -$332K -4,373 -6%
DWM
527
Dorchester Wealth Management
Quebec, Canada
$4.83M -$170K -2,245 -3%
FFA
528
First Foundation Advisors
California
$4.8M -$2.08M -27,342 -29%
NFA
529
Nuveen Fund Advisors
Illinois
$4.79M -$1.63M -21,424 -24%
OAC
530
OMERS Administration Corp
Ontario, Canada
$4.73M +$2.14M +28,200 +75%
BCM
531
Bluefin Capital Management
New York
$4.72M +$1.52M +20,001 +44%
BA
532
Boston Advisors
Massachusetts
$4.72M -$23.3M -306,527 -82%
BIP
533
Brandes Investment Partners
California
$4.71M -$339K -4,466 -6%
KC
534
Kepos Capital
New York
$4.7M +$1.98M +26,041 +66%
WS
535
Wedbush Securities
California
$4.66M +$50.1K +660 +1%
BCM
536
Brookmont Capital Management
Texas
$4.65M +$1.64M +21,628 +50%
FIM
537
Freedom Investment Management
Connecticut
$4.62M -$129K -1,693 -3%
BIAS
538
Beacon Investment Advisory Services
New Jersey
$4.59M +$33K +434 +0.7%
ACC
539
Accident Compensation Corp
New Zealand
$4.59M +$152K +2,000 +3%
AIP
540
Ameritas Investment Partners
Nebraska
$4.59M -$263K -3,466 -5%
LG
541
LaFleur & Godfrey
Michigan
$4.56M +$4.83M +63,632 New
ST
542
Sentinel Trust
Texas
$4.51M -$2.68M -35,280 -36%
CC
543
Cornerstone Capital
California
$4.51M +$891K +11,730 +23%
EGA
544
Eagle Global Advisors
Texas
$4.5M +$30.5K +402 +0.6%
OIA
545
Optimum Investment Advisors
Illinois
$4.49M -$104K -1,375 -2%
QOP
546
Quinn Opportunity Partners
Virginia
$4.47M -$45.6K -600 -1%
CCA
547
Cobblestone Capital Advisors
New York
$4.46M -$499K -6,570 -10%
UAS
548
United Asset Strategies
New York
$4.43M -$684K -9,008 -13%
VFA
549
Virtus Fund Advisers
Connecticut
$4.41M +$891K +11,735 +24%
TAM
550
Trillium Asset Management
Massachusetts
$4.37M -$53.8K -709 -1%

GILD Hedge Fund Activity: Q4 2017 in Review

1,575 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2017, worth a combined $73.2B — down 10% from $81.5B a quarter earlier.

Buyers outnumbered sellers: 202 funds opened new GILD positions and 116 closed out — a net gain of 86 holders — while 535 added to existing stakes and 691 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $794M. The largest seller was C WorldWide Group, cutting an estimated $300M.

  • 1,575 institutional investors held Gilead Sciences (GILD) as of Q4 2017, up from 1,504 in Q3 2017.
  • Funds reported $73.2B of Gilead Sciences stock for Q4 2017, down 10% quarter-over-quarter.
  • 202 funds opened new Gilead Sciences positions in Q4 2017 and 116 closed out, a net change of +86 holders.
  • The largest Gilead Sciences buyer in Q4 2017 was Capital Research Global Investors, an estimated $794M added.
  • The largest Gilead Sciences seller in Q4 2017 was C WorldWide Group, an estimated $300M sold.

Based on aggregated 13F filings for Q4 2017.